Cargando…
P985: CLL-1 IS AN ADOPTIVE IMMUNOTHERAPY TARGET IN JUVENILE MYELOMONOCYTIC LEUKEMIA
Autores principales: | Huebner, Juwita, Xirenayi, Sherin, Rivera, Jose, Patiño Escobar, Bonell, Lee, Alex G, Mandal, Kamal, Diaz-Flores, Ernesto, Wiita, Arun, Stieglitz, Elliot |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431425/ http://dx.doi.org/10.1097/01.HS9.0000970844.40333.db |
Ejemplares similares
-
P998: TRETINOIN AND CALCITRIOL ENHANCE TREATMENT REGIMENS FOR JUVENILE MYELOMONOCYTIC LEUKEMIA IN EX VIVO DRUG SENSITIVITY ASSAYS
por: Stieglitz, Elliot, et al.
Publicado: (2023) -
Unraveling the surface proteomic profile of multiple myeloma to reveal new immunotherapeutic targets and markers of drug resistance
por: Patiño-Escobar, Bonell, et al.
Publicado: (2022) -
Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay
por: Stieglitz, Elliot, et al.
Publicado: (2023) -
Juvenile myelomonocytic leukemia in the molecular era: a clinician’s guide to diagnosis, risk stratification, and treatment
por: Wintering, Astrid, et al.
Publicado: (2021) -
Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples
por: Behnert, Astrid, et al.
Publicado: (2021)